Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Chalmers Ventures the top university incubator in the Nordics

Chalmers Ventures is the top university incubator in the Nordics, and in the top 10 globally, according to the latest rankings from UBI Global. Chalmers Ventures was also praised for its effective gender equality work, and was recognised in the category ‘Most Promising – Women Founders’. On 6 November, at the World Incubation Summit 2019 in Doha, Qatar, the top incubators from around the globe were recognised for their work in promoting entrepreneurship. The top programs outperformed their global peers with regard to the value they provide to their innovation ecosystems and client start-

SEMAFO: Update on Attack on the Public Road Between Fada and Boungou

Montreal, Quebec, November 7, 2019 /CNW/ – SEMAFO Inc. (TSX, OMX: SMF) (“SEMAFO”) provides an update on yesterday’s attack on the public road between Fada and the Boungou Mine site in the Est region of Burkina Faso. The incident happened approximately 40 kilometers from the Boungou Mine. The convoy, escorted by military personnel, comprised five buses transporting SEMAFO national employees, contractors and suppliers. Information from Burkina Faso authorities, currently has 37 fatalities and 60 wounded. Benoit Desormeaux, President and CEO of SEMAFO, states: “We are devastated by this

Calmark receives approval from the Swedish Ethical Review Authority to conduct clinical trial at Södersjukhuset

The Swedish Ethical Review Authority has decided to approve Calmark Sweden AB's application regarding a study on newborns. The application covers the Company’s three biomarkers and comprises three parts, which will be conducted within the next few months.The Swedish Ethical Review Authority’s approval is a prerequisite for conducting a clinical trial involving patients. Calmark is planning three study parts on each of the Company's biomarkers, which will be carried out in cooperation with the children's hospital Sachsska barn- och ungdomssjukhuset, a part of Södersjukhuset. The application

Invitation to the presentation of BIMobject’s 2019 Q3 report

On Friday November 15 at 08.00 CET, BIMobject will publish its Q3 report. At 14.00 CET on the same day, BIMobject will hold an audiocast with a conference call in which CEO Carl Silbersky and CFO Alexander Dahlquist will present the report.   The presentation will be held in English and can be followed online or by phone. Questions may be asked verbally via teleconference, or in writing via the online audiocast. To join the presentation, please use one of the following methods: Online audiocast: https://tv.streamfabriken.com/bimobject-q3-2019 Teleconference numbers below:SE:

Cabonline expands in Norway

Cabonline in Norway has acquired Miljötaxi Stavanger A/S. Through the acquisition, Cabonline doubles its car fleet in Stavanger to over 80 cars. The cars that drive for Miljötaxi Stavanger are all hybrid vehicles and Cabonline is thus taking a step further towards its sustainability goal – a fossil fuel independent vehicle fleet.For information:Peter Viinapuu, CEO, tel +46 76 641 10 06 About Cabonline GroupCabonline Group is a leading technology and service provider for the taxi industry in the Nordics. In Sweden, Finland, Norway and Denmark, around 3,000 transporters are connected

AIO Liquid Cooling Solution Maximizes the Performance of the World’s Fastest 16-Core Consumer Desktop Processor, AMD Ryzen™ 9 3950X

Incredible Performance Best Experienced with a Liquid Cooling SolutionAalborg, Denmark – November 7, 2019 –– Enthusiasts rejoice! With the announcement  of the highly anticipated flagship 16-core consumer desktop processor – AMD Ryzen™ 9 3950X – AMD is recommending enthusiasts use all-in-one (AIO) liquid cooling solutions, such as Asetek technology, to take full advantage of the industry-leading performance offered by the world’s fastest 16-core consumer desktop

Invitation to the presentation and Q&A of the interim report

On the 14th of November at 10:00 CET, Speqta will hold a meeting for shareholders, media and other stakeholders to present their interim report to be published for Q3. Participants will be able to attend on-site via the registration instructions below or can alternatively follow the presentation via webcast.CEO Fredrik Lindros will present the report, which will be followed by a Q&A session. There will be opportunities to ask questions via webcast, and presentation materials will be included.The interim report will be released on November 14th at 08:30 CET.Time: Thursday

Componenta lowers its guidance for net sales in 2019

Componenta Corporation, Stock Exchange Release, Insider Information, 7 November 2019 at 15.25 Componenta lowers its guidance for 2019 net sales, due to the specified classification of Componenta Främmestad AB as discontinued operations. The company expects the net sales of the Group’s continued operations for 2019 (including Komas Oy as of 1 September 2019 but entirely without Componenta Främmestad AB) to be in the range of EUR 45 – 55 million after the intra-group income and expenses between continued and discontinued operations have been eliminated in their entirety. The guidance

Componenta presents its previously published consolidated income statements and financial key figures adjusted with the impact of Componenta Främmestad AB’s bankruptcy

Componenta Corporation, Stock Exchange Release, on 7 November 2019 at 15.25 Componenta has restated its consolidated income statements for the year 2018 and six months period ended 30 June 2019 due to bankruptcy of Componenta Främmestad AB. Componenta’s Sweden-based subsidiary Componenta Främmestad AB filed an application for bankruptcy with the local district court on 25 September 2019. Since the loss of control Componenta has classified and reports Componenta Främmestad AB as discontinued operations. Componenta applies the requirements of IFRS 5 Non‑current Assets Held for Sale and

#19-1124 Change to certain derivative on NGM

As from November 8, 2019, certain instrument issued by Natixis Structured Issuance SA is subject to change.For more details see attached file. For further information concerning this NGM notice please contact: Listing on +46 8 566 390 20 or at listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded

SBB cancels repurchased SEK perpetual capital securities

NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) OR IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT. THE DISTRIBUTION OF THIS DOCUMENT IN CERTAIN JURISDICTIONS (IN PARTICULAR, THE UNITED STATES AND

Cline Scientific AB Acquires Liv Diagnostics AB to Further Their Breast Cancer Diagnostics Initiative

Gothenburg, Sweden, November 7,2019: Cline Scientific is announcing the acquisition of the Gothenburg based Liv Diagnostics. The boards of Cline Scientific and Liv Diagnostics have agreed to a deal where Cline buys Liv and their business for cash (share capital) and a possibility of an Additional Purchase Price when the business is divested. Thus, the transaction does not result in dilution of Clines stock.The two companies have worked in close collaboration since Liv was founded in 2016. Liv Diagnostics is currently a part of AstraZeneca’s bioventure hub. As Cline Scientific strengthens

New data show positive outcome when using OSSDSIGN Cranial PSI for cranial reconstruction

OssDsign AB (publ) (“OssDsign” or the “Company”) today announced that updated outcome data on the use of OSSDSIGN Cranial PSI in 670 cases of cranioplasty and cranial reconstructions have been made public via the company’s website. All data were collected as part of post-market surveillance of product performance in Europe, US and selected Asian markets in compliance with MEDDEV 2.7/1 rev.4 and MDR 2017/745. After a median follow-up time of 17 months, rate of infections leading to implant removal remained low at 2.4%.Reconstruction of cranial defects can be a complex surgical procedure

Secure Thingz wins prestigious Company of the Year category at last night’s TechWorks Awards

Cambridge, England—November 7, 2019—Secure Thingz®, a global domain expert in device security, embedded systems and lifecycle management, are proud to announce that it has been declared 2019’s Company of the Year at last night’s TechWorks Awards. Founded in 2016 and part of IAR Systems since 2018, Secure Thingz is focused on delivering advanced security solutions into the emerging industrial Internet of Things, critical infrastructure, automotive and other markets. It is one of the world’s leading IoT security experts and enables organisations to implement straightforward, scalable and

Finnair updates its financial targets, aims for sustainable profitable growth

Finnair Plc          Stock Exchange Release          7 November 2019 at 15:00 CET Following a period of accelerated growth, Finnair is now moving into a new phase. The company seeks to grow in line with the market, targeting sustainable and profitable growth. Finnair’s Board of Directors has defined the following targets for the 2020-2025 strategy period: · Comparable EBIT of over 7.5% over the cycle (at constant fuel and currency), after a 12-18 month build-up period · ROCE of over 10% over the cycle (at constant fuel and currency), after a 12-18 month build-up period · On-

Revenio Group Corporation: Managers' Transactions

Stock Exchange Release, Managers' Transactions, November 7, 2019 at 15.00Revenio Group Corporation - Managers' Transactions____________________________________________ Person subject to the notification requirementName: Karvo TomiPosition: Other senior manager(X) Legal personIssuer: Revenio Group CorporationLEI: 743700I27E0FWSXLKK04 Notification type: INITIAL NOTIFICATIONReference number: 743700I27E0FWSXLKK04_20191107144616_2____________________________________________ Transaction date: 2019-11-01Venue: FIRST NORTH FINLAND (FNFI)Instrument type: FINANCIAL

BrainCool AB (publ) has completed the recruitment in the Nordic clinical study with Cooral® System to prevent oral mucositis (OM)

The recruitment to the Nordic study to prevent oral mucositis is now completed. The study is a controlled, randomized Nordic study of 180 patients treated with powerful cytostatic therapy due to malignant blood disorders. In the study, BrainCool's product Cooral® System was evaluated to prevent troublesome mucosal damage in the oral cavity and pharynx (oral mucositis, OM). “The completed recruitment is an important milestone for BrainCool and Cooral® System. I am extremely grateful for the team's hard work at the clinics”- says Martin Waleij, CEO of BrainCool AB. The analysis of the

Teleste continues collaboration for Smart City solutions as a part of the LuxTurrim5G ecosystem

Turku, Finland – 7 November 2019 – Teleste continues building key enablers for the smart and safe city in the LuxTurrim5G ecosystem project that has entered its second phase  and is moving towards productization and practical piloting of 5G based smart city innovations. With a special focus on the needs for public safety and intelligent public transport, Teleste collaborates with altogether 26 ecosystem partners in the two-year intensive co-development driven by Nokia and coordinated by

STENOCARE sign supply agreement with Emerald Health Therapeutics Inc

STENOCARE A/S (“STENOCARE”) hereby announce that the company has signed a new agreement to source medical cannabis for Denmark and the company’s international markets with the Canadian company Emerald Health Therapeutics Inc (“Emerald”) (TSXV: EMH; OTCQX: EMHTF). STENOCARE and Emerald will immediately commence the work with the Danish Medicines Agency (“DMA”) to have the products approved for the Danish Medical Cannabis Pilot Programme.STENOCARE has carefully evaluated potential new suppliers of medical cannabis in order to supply products suitable for patients according to the strict

Change in Valmet Oyj’s holding of treasury shares

Valmet Oyj’s stock exchange release on November 7, 2019 at 2:00 p.m. EET On November 7, 2019 a total of 472 Valmet shares have been returned free of consideration to Valmet Oyj according to the terms and conditions of the long-term incentive plan 2018-2020. Originally, the shares were transferred to the participants after the 2018 performance period of the plan. Including the returned shares, Valmet Oyj now holds a total of 246,096 treasury shares. Further information, please contact:Pekka Rouhiainen, Director, Investor Relations, Valmet, tel. +358 10 672 0020 VALMET Kari

Norway Royal Salmon (NRS): Invitation to presentation of Q3 2019

Norway Royal Salmon will present the interim report for the 3rd quarter 2019 on Tuesday 12th November 2019 at hrs 08:00 CET at Hotel Continental, Stortingsgaten 24/26 in Oslo. The company’s CEO Charles Høstlund and CFO Ola Loe will announce the results. Please note that the quarterly report and presentation will be published at 06:30 CET. For further information, please contact:CFO Ola LoeTlf: +47 911 79 411E-mail: ola.loe@salmon.no

BerGenBio to present clinical data from Phase II combination trial of bemcentinib and LDAC trial in elderly AML patients at ASH 2019

Bergen, Norway, 7 November 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, is pleased to announce it has been accepted for a poster presentation at the 61st Annual American Society of Hematology (ASH) Meeting, which takes place from 7-10 December 2019 in Orlando, Florida. The poster will provide an update on its phase II study of bemcentinib (BGB324) in combination with Low-dose Cytarabine in elderly AML patients. Abstract titles have been announced online 

Invent Medic receives first Efemia order from a Swedish public health care region

Invent Medic announces that the company has received the first order for the product Efemia Bladder Support from a Swedish public health care region. The order shows that health care entities value the benefits of Efemia as a non-surgical, effective and easy-to-use solution for women with stress urinary incontinence (SUI).As stated in Invent Medic’s recently published interim report, the company is a registered as a provider for two Swedish health care regions. The registration enables these regions to order Efemia before finalising public procurements. In addition to being registered as

There are no items matching the current filter
There are no more items matching the current filter
Back to top